Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Ophthalmic Genet. 2022 Apr;43(2):201-209. doi: 10.1080/13816810.2021.1998554. Epub 2021 Nov 9.
To establish the molecular diagnosis in two brothers presenting with the ocular features of Knobloch Syndrome using whole genome sequencing (WGS).
Clinical examination and ophthalmological phenotyping were completed under general anaesthesia. DNA samples were tested on a targeted retinal dystrophy next-generation sequencing panel. Subsequently, WGS was performed to identify additional variants.
Clinical examination confirmed the diagnosis of Knobloch Syndrome. Targeted sequencing identified a novel heterozygous frameshift pathogenic variant in , c.2864dupC; p.(Gly956ArgfsX20), inherited from their mother. A second paternally inherited heterozygous missense variant was identified in both brothers, c.5014 G > A; p.(Asp1672Asn), which was initially considered to have too high frequency to be pathogenic (MAF 8.8%). This led to an in-depth analysis of the locus using WGS data, which confirmed that Asp1672Asn is a likely pathogenic hypomorphic allele.
To date, all confirmed genetic diagnoses of Knobloch syndrome are attributable to variants in . The family described here has a heterozygous novel loss of function variant. Detailed analysis of WGS data combined with family segregation studies concluded that although Asp1672Asn has a high population frequency, it is the most likely second pathogenic variant in our family. This supports the hypothesis that this is a hypomorphic allele, which, in combination with a loss of function pathogenic variant, leads to Knobloch syndrome.To our knowledge, this is the first time that WGS has been used to confirm a molecular diagnosis of Knobloch syndrome in this way and has provided further insight into the molecular mechanisms in this rare disorder.
使用全基因组测序(WGS)对表现出 Knobloch 综合征眼部特征的两兄弟进行分子诊断。
在全身麻醉下进行临床检查和眼科表型分析。对靶向视网膜变性下一代测序面板进行 DNA 样本测试。随后,进行 WGS 以识别其他变体。
临床检查证实了 Knobloch 综合征的诊断。靶向测序在 基因中发现了一个新的杂合移码致病性变异,c.2864dupC;p.(Gly956ArgfsX20),从他们的母亲那里遗传。在两兄弟中均发现了第二个父系遗传的杂合错义变异,c.5014G>A;p.(Asp1672Asn),最初认为其频率过高而不可能致病(MAF 8.8%)。这导致使用 WGS 数据对 基因进行了深入分析,证实 Asp1672Asn 是一种可能的致病功能减弱等位基因。
迄今为止,Knobloch 综合征的所有已确认遗传诊断都归因于 基因中的变异。这里描述的家族有一个杂合的新型功能丧失变异。对 WGS 数据的详细分析结合家族分离研究得出结论,尽管 Asp1672Asn 具有较高的人群频率,但它是我们家族中最有可能的第二个致病变异。这支持这样一种假说,即这是一个功能减弱的等位基因,与功能丧失的致病性变异相结合,导致 Knobloch 综合征。据我们所知,这是首次使用 WGS 以这种方式确认 Knobloch 综合征的分子诊断,并为这种罕见疾病的分子机制提供了进一步的见解。